TVTX (Travere Therapeutics) Cyclically Adjusted Book per Share: $5.41 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TVTX Travere Therapeutics Inc TVTX
61 GF Score
Price $65.71
GF Value $36.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Travere Therapeutics Cyclically Adjusted Book per Share?

Travere Therapeutics TVTX +1.96% 61 Cyclically Adjusted Book per Share is $5.41 as of Jun. 2026. GuruFocus rates TVTX with a GF Score™ of 61/100 and a GF Value™ of $36.75 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Travere Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was $0.260. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.41 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Travere Therapeutics's average Cyclically Adjusted Book Growth Rate was -13.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Travere Therapeutics was 13.30% per year. The lowest was 1.30% per year. And the median was 8.80% per year.

As of today (2026-08-22), Travere Therapeutics's current stock price is $65.705. Travere Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $5.41. Travere Therapeutics's Cyclically Adjusted PB Ratio of today is 12.15.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Travere Therapeutics was 12.16. The lowest was 0.84. And the median was 3.91.


Travere Therapeutics  (NAS:TVTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Travere Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=65.705/5.41
=12.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Travere Therapeutics was 12.16. The lowest was 0.84. And the median was 3.91.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Travere Therapeutics Cyclically Adjusted Book per Share Related Terms


Travere Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Travere Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Travere Therapeutics Cyclically Adjusted Book per Share Chart

Travere Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.98 5.58 6.10 6.42 5.80

Travere Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.27 6.06 5.80 5.63 5.41

TVTX vs ORKA, DNTH, SRRK: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Travere Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Travere Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Cyclically Adjusted PB Ratio falls into.


TVTX
61GF Score
Travere Therapeutics Inc TVTX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Travere Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Travere Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.26/333.9520*333.9520
=0.260

Current CPI (Jun. 2026) = 333.9520.

Travere Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 8.158 241.428 11.284
201612 8.119 241.432 11.230
201703 7.886 243.801 10.802
201706 7.726 244.955 10.533
201709 7.752 246.819 10.489
201712 7.445 246.524 10.085
201803 7.511 249.554 10.051
201806 7.134 251.989 9.454
201809 7.750 252.439 10.252
201812 7.689 251.233 10.221
201903 6.895 254.202 9.058
201906 6.459 256.143 8.421
201909 5.726 256.759 7.447
201912 5.133 256.974 6.671
202003 5.231 258.115 6.768
202006 6.260 257.797 8.109
202009 5.907 260.280 7.579
202012 4.043 260.474 5.184
202103 6.001 264.877 7.566
202106 5.474 271.696 6.728
202109 5.037 274.310 6.132
202112 4.834 278.802 5.790
202203 3.277 287.504 3.806
202206 2.455 296.311 2.767
202209 1.569 296.808 1.765
202212 0.667 296.797 0.750
202303 2.536 301.836 2.806
202306 1.554 305.109 1.701
202309 3.725 307.789 4.042
202312 2.664 306.746 2.900
202403 0.973 312.332 1.040
202406 0.198 314.175 0.210
202409 -0.391 315.301 -0.414
202412 0.676 315.605 0.715
202503 0.370 319.799 0.386
202506 0.368 322.561 0.381
202509 0.822 324.800 0.845
202512 1.263 324.054 1.302
202603 1.068 330.213 1.080
202606 0.260 333.952 0.260

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $5.41 mean?
Travere Therapeutics (TVTX) has a Cyclically Adjusted Book per Share of $5.41 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Travere Therapeutics and its competitors.
Is Travere Therapeutics' Cyclically Adjusted Book per Share too high?
Travere Therapeutics' current Cyclically Adjusted Book per Share is $5.41. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Cyclically Adjusted Book per Share compare to ORKA and DNTH?
Travere Therapeutics' Cyclically Adjusted Book per Share of $5.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Travere Therapeutics and its competitors. Travere Therapeutics's current Cyclically Adjusted Book per Share is $5.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is $5.41. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Cyclically Adjusted Book per Share is $5.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Travere Therapeutics (TVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued. The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75. GuruFocus considers Travere Therapeutics to be Significantly Overvalued.

Key valuation signals for TVTX:

  • Cyclically Adjusted Book per Share: $5.41
  • GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Travere Therapeutics Business Description

Address 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score

Get the complete analysis for TVTX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.71
Price
$36.75
GF Value